Trevi Therapeutics (NASDAQ:TRVI) Shares Down 3.3% - Time to Sell?

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report)'s share price fell 3.3% during mid-day trading on Monday . The stock traded as low as $6.38 and last traded at $6.52. 988,511 shares changed hands during mid-day trading, a decline of 51% from the average session volume of 2,002,676 shares. The stock had previously closed at $6.75.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TRVI. B. Riley reiterated a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday. D. Boral Capital restated a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday. Needham & Company LLC reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. Oppenheimer raised their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Finally, Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $17.56.

Trevi Therapeutics Stock Performance

The firm's 50-day moving average price is $4.55 and its two-hundred day moving average price is $3.73. The firm has a market capitalization of $494.25 million, a price-to-earnings ratio of -14.64 and a beta of 0.90.

Remove Ads

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. As a group, equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares of the company's stock, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 24.37% of the stock is owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently bought and sold shares of TRVI. Frazier Life Sciences Management L.P. increased its position in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after acquiring an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Trevi Therapeutics during the fourth quarter worth $17,099,000. Vivo Capital LLC increased its position in shares of Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after acquiring an additional 1,875,000 shares in the last quarter. Woodline Partners LP increased its position in shares of Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after acquiring an additional 2,606,370 shares in the last quarter. Finally, MPM Bioimpact LLC increased its position in shares of Trevi Therapeutics by 101.2% during the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock worth $12,751,000 after acquiring an additional 1,556,379 shares in the last quarter. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.